Cite
APA Citation
Tam, C., Quach, H., Nicol, A., Badoux, X., Rose, H., Prince, H., Leahy, M., Eek, R., Wickham, N., Patil, S., Huang, J., Zhang, X., Wang, L., Hedrick, E., Novotny, W., & Flinn, I. (n.d.). sAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB‐3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Hematological oncology, 35, 113. http://access.bl.uk/ark:/81055/vdc_100047428638.0x00001f